ELRIG’s two-day Drug Discovery 2016, featuring world-class speakers on the latest scientific breakthroughs and new approaches in drug discovery research, returns to Liverpool in the autumn after several years away.
The flagship Drug Discovery event, 13-14th October 2016 at the Arena & Convention Centre Liverpool, is the UK’s largest free to attend event of its kind. It will bring together industry leaders from across the pharma, biotech, academia and vendor communities to discuss future opportunities for novel therapeutic discovery.
Professor Sir Munir Pirmohamed, one of the country’s leading clinical experts, based at University of Liverpool, will be Plenary Speaker at this event. Professor Pirmohamed will speak on Drug Safety in Drug Development.
The six main sessions will cover: Innovations In Chemistry; Oncology & Immunology; Innovations in Predictive & Translational Models; Assay Development, Screening & Emerging Technologies; Coming Closer to the Patient – Cells and Genes in Therapy and Diagnostics; and Target Identification & Validation.
The conference will also explore innovative technologies and approaches that can be used to overcome drug development challenges.
Another addition to the conference this year is a series of Core Technologies Workshops & Vendor Tutorials. These will provide a more informal, interactive environment for attendees to discuss key issues and future directions in workshops coordinated by leaders in the fields.
Dr Peter Simpson, director of N8 Research Partnership, which is partnering with ELRIG, and who co-chaired last year’s Drug Discovery conference, said:
“This event will be a superb opportunity to hear about high quality science, from leading thinkers and innovators as they challenge and disrupt previous thinking.
“As Director of N8, I’m absolutely convinced that bringing the whole community of academia, SMEs and major companies together truly fosters innovation and collaboration. It is great that this event is returning to the North, a region where Health Innovation is highlighted as a major economic capability. Great advancement will come from quality research insights, informal discussions, and networking, to the benefit the drug discovery and life science communities.”
Steve Rees, Chair of ELRIG and VP of Screening Sciences and Sample Management at AstraZeneca, said: “Typically attracting 1200 attendees, the Drug Discovery meeting provides a unique opportunity for scientists from academia, biotech, pharma and the vendor community to hear world leading speakers describe advances in target identification and preclinical drug discovery.
“We are delighted to bring our 10th anniversary meeting to Liverpool and look forward to welcoming scientists from the N8 Universities to the meeting.”
There are still free delegate places remaining and there will be the chance to view relevant exhibits, vendors and poster displays.